Bio Optical Detection

Bio Optical Detection S.L. (biod) was initially conceived by scientists from the Optics, Photonics and Bio-Photonics research group based at the Centre of Biomedical Technology, Technical University of Madrid. After its founding in 2010, the company focused primarily on R&D activities in collaboration with public and private institutions (e.g., the then Spanish Ministry of Economics and Competitiveness, which funded ATAPoC, a point-of-care allergy diagnostic project (Grant RTC-2015-3273-1), and Horus Pharma, which funded development of our first technology demonstrator through an engineering contract).

In 2017, a new shareholder joined biod, providing €130,000 of seed money, and the company pivoted towards bringing its own solution to the market. Since autumn 2017, it has been the lead commercial partner within the project AllerScreening (a research and innovation action supported by the EU Horizon 2020 programme, Grant 768641). To further support its growth plans, biod has begun offering screening services for pharmaceutical companies, generating its first revenues not derived from R&D projects.

In November 2019, biod presented a fully functional allergy diagnostic device (TRL 6) at MEDICA 2019 in Düsseldorf, Europe’s largest medical industry trade fair. Currently, we are working to commercialise the device, with the market launch planned for 2022.